10X Genomics, Inc. Stock Price, News & Analysis

10x Genomics (Nasdaq: TXG) announced its participation in two upcoming investor conferences. The William Blair 41st Annual Growth Stock Conference will feature a fireside chat on June 2, 2021, at 2:20 p.m. ET. Following this, the Goldman Sachs 42nd Annual Global Healthcare Conference will include a fireside chat on June 9, 2021, at 3:50 p.m. ET. Interested parties can access live and archived webcasts on the company's website.

10x Genomics specializes in life science technologies aimed at advancing human health, with a robust patent portfolio and significant global research adoption.

10x Genomics (TXG) reported a strong Q1 2021 with revenue of $105.8 million, up 47% year-over-year from $71.9 million in Q1 2020. The growth was driven by increased consumables revenue linked to a larger instrument installed base. Gross margin improved to 84%, up from 79% the previous year. Despite a $10.2 million operating loss, the net loss reduced to $11.6 million from $21.1 million. The company maintains full-year revenue guidance of $480 million to $500 million, indicating a potential 61% to 67% growth over 2020.

10x Genomics, Inc. (Nasdaq: TXG) has announced its participation in the BofA Securities 2021 Virtual Healthcare Conference. The management is scheduled to present on May 12, 2021, at 3:30 p.m. ET. Interested individuals can access a live and archived webcast of the presentation via the company's website under the 'Investors' section.

10x Genomics focuses on life science technology, providing integrated solutions, including instruments and software, to analyze biological systems. The company has a notable patent portfolio with over 1,000 patents and is widely adopted by leading global research institutions.

10x Genomics (Nasdaq: TXG) will release its Q1 2021 financial results on May 5, 2021, after market close. A live webcast is scheduled for 1:30 PM PT to discuss these results along with business developments and future outlook. The webcast will be accessible through the company's website and will be archived for at least 45 days. 10x Genomics focuses on providing innovative life science technology solutions that enhance biological research and has a robust patent portfolio.

10x Genomics, Inc. (TXG) announced the launch of its Chromium Single Cell Gene Expression Low Throughput (LT) Kit, aimed at making single cell analysis more accessible to researchers. This innovative kit significantly reduces the startup costs for experiments. The LT Kit is designed for experiments ranging from a few hundred cells to high-throughput studies.

Additionally, the CellPlex solution allows multiplexing of up to 96 samples on a single chip, enhancing experimental capability. Both products facilitate cost-effective research and are part of 10x Genomics' commitment to democratizing scientific discovery.

10x Genomics (TXG) has announced significant expansion plans in Pleasanton, California, involving a $29.4 million acquisition of the former Pleasanton Plaza retail complex. The new site at 1701 Springdale Avenue will feature 381,000 square feet of lab space and a parking garage, with completion expected by 2023. This move reinforces the company’s commitment to its headquarters, where it has grown to over 900 employees. Pleasanton will rename Fabian Court to 'Genomics Place' in recognition of 10x's investment.

10x Genomics (Nasdaq: TXG) announced its participation in the 41st Annual Cowen Health Care Conference on March 3 at 2 p.m. Eastern Time. The presentation will be accessible via a live and archived webcast on the company's website. 10x Genomics is focused on advanced life science technologies, with products adopted by top research institutions and pharmaceutical companies globally. The company boasts a robust patent portfolio with over 1,000 patents and has been cited in over 2,200 research papers in various fields.

10x Genomics (Nasdaq: TXG) has announced the acquisition of Tetramer Shop and unveiled new products at its Xperience 2021 event. This marks the fifth acquisition for the firm, aimed at bolstering its immunology efforts. The newly introduced products focus on single-cell analysis, with significant capabilities like the Low Throughput Single Cell Gene Expression solution, expected to lower startup costs by up to 60%. Other upcoming innovations include Chromium X, Visium advancements, and a new cloud platform for data analysis, enhancing accessibility for researchers.

10x Genomics reported Q4 2020 revenue of $112.2 million, a 49% increase from the previous year, and a full-year revenue of $298.8 million, up 22% year-over-year. The company had a gross margin of 83% in Q4, up from 78% in Q4 2019, driven by a shift in product sales. However, operating expenses surged to $502.9 million, resulting in an operating loss of $409.6 million. For 2021, 10x Genomics projects revenue between $480 million and $500 million, reflecting a growth outlook of 61% to 67%.